Mutations induced in the NS5B gene of bovine viral diarrhea virus by antiviral treatment convey resistance to the compound.

Bovine viral diarrhea virus (BVDV) is a widespread bovine pathogen for which there is no specific therapeutic agent. A previous study using 2-(2-benzimidazolyl)-5-[4-(2-imidazolino)phenyl]furan dihydrochloride (DB772) to treat calves persistently infected with BVDV resulted in a decrease in the viral load of infected calves but treatment resulted in the rapid selection of drug-resistant mutant isolates. In this article we describe three mutations found in the mutant isolates associated with in vivo and in vitro resistance to DB772. All three mutations are found in the NS5B which functions as the RNA-dependent-RNA-polymerase during viral replication. Growth curves for the mutant isolates were not largely different from those of wild-type isolates when cultured in the absence of DB772. Thus, DB772 appears to act by binding to the specified domain but binding is disrupted or inhibited by the described mutation.

The imidazopyrrolopyridine analogue AG110 is a novel, highly selective inhibitor of pestiviruses that targets the viral RNA-dependent RNA polymerase at a hot spot for inhibition of viral replication.

Ethyl 2-methylimidazo[1,2-a]pyrrolo[2,3-c]pyridin-8-carboxylate (AG110) was identified as a potent inhibitor of pestivirus replication. The 50% effective concentration values for inhibition of bovine viral diarrhea virus (BVDV)-induced cytopathic effect, viral RNA synthesis, and production of infectious virus were 1.2 +/- 0.5 microM, 5 +/- 1 microM, and 2.3 +/- 0.3 microM, respectively. AG110 proved inactive against the hepatitis C virus and a flavivirus. AG110 inhibits BVDV replication at a time point that coincides with the onset of intracellular viral RNA synthesis. Drug-resistant mutants carry the E291G mutation in the viral RNA-dependent RNA polymerase (RdRp). AG110-resistant virus is cross-resistant to the cyclic urea compound 1453 which also selects for the E291G drug resistance mutation. Moreover, BVDV that carries the F224S mutation (because of resistance to the imidazopyridine 5-[(4-bromophenyl)methyl]-2-phenyl-5H-imidazo[4,5-c]pyridine [BPIP]and VP32947) is also resistant to AG110. AG110 did not inhibit the in vitro activity of recombinant BVDV RdRp but inhibited the activity of BVDV replication complexes (RCs). Molecular modeling revealed that E291 is located in a small cavity near the tip of the finger domain of the RdRp about 7 A away from F224. Docking of AG110 in the crystal structure of the BVDV RdRp revealed several potential contacts including with Y257. The E291G mutation might enable the free rotation of Y257, which might in turn destabilize the backbone of the loop formed by residues 223 to 226, rendering more mobility to F224 and, hence, reducing the affinity for BPIP and VP32947. It is concluded that a single drug-binding pocket exists within the finger domain region of the BVDV RdRp that consists of two separate but potentially overlapping binding sites rather than two distinct drug-binding pockets.

[Study of antiviral activity of different drugs against bovine herpes virus and pestivirus]. / Izuchenie antivirusnykh svoistv preparatov razlichnogo proiskhozhdeniia v otnoshenii gerpes- i pestivirusov krupnogo rogatogo skota.

In vitro antiviral activity of 11 different drugs against the viruses of infectious bovine rhionotracheitis (IBR) and bovine viral diarrhea (BVD) was studied. The ID50 of the drugs were determined in monolayers of cell cultures MDBK and KCT: 20 mcg/ml for anandin, 25 mcg/ml for polyprenole, 50 mcg/ml for bromuridin, methisazone, aciclovir, gossypole, ribavirin and liposomal ribavirin, 100 mcg/ml for eracond, and 200 mcg/ml for phosprenil and argovit. Phosprenil was the only drug that showed virucidal activity against the IBR virus. All the drugs inhibited reproduction of the IBR virus in sensitive cell culture MDBK: 100,000-fold inhibition by bromuridin, aciclovir, ribavirin and methisazone, 1000-10000-fold inhibition by liposomal ribavirin, gossypole, anandin, polyprenole and phosprenil, 100-fold inhibition by eracond and argovit. As for the BVD virus, bromuridin, phosprenil, polyprenole, methisazone, aciclovir, gossypole, argovit, ribavirin and liposomal ribavirin also showed their activity in cell culture KCT (100-10,000-fold inhibition). The other drugs were ineffective.